Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
about
Rotenone, paraquat, and Parkinson's diseaseThe spectrum of disease in chronic traumatic encephalopathyThe synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementiaThe genetic epidemiology of neurodegenerative disease.Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populationsDopamine transporter imaging for the diagnosis of dementia with Lewy bodies18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s dementia and other dementias in asymptomatic and previously clinically unevaluated people aged over 65 years in community and primary care populations11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI)Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Psychological treatments for depression and anxiety in dementia and mild cognitive impairmentPlasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care settingCholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's diseaseDopamine transporter imaging for the diagnosis of dementia with Lewy bodiesThe accuracy of 18 FDG-PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCIPlasma and Cerebro Spinal Fluid Amyloid Beta 42, 40 and the 42:40 ratio for diagnosis of incipient Dementia in a population with objective cognitive declinePlasma and CSF Abeta for the longitudinal prediction of Alzheimer's disease dementia and other dementias in people with cognitive decline but no dementiaPlasma and Cerebro Spinal Fluid Amyloid Beta 42, 40 and the 42:40 ratio for diagnosis of incipient Dementia in a population with objective cognitive declineCholinesterase inhibitors for Parkinson's disease dementiaCholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's diseaseMisfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathiesConceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative diseaseValidation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed casesDementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer's diseaseThe prevalence and causes of dementia in people under the age of 65 yearsBeta-synuclein gene alterations in dementia with Lewy bodies.Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosisTraumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotypeAssessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET)18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Cholinergic imaging in dementia spectrum disordersGenetics Underlying Atypical Parkinsonism and Related Neurodegenerative DisordersBrain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participantsThe clinical problem of symptomatic Alzheimer disease and mild cognitive impairmentDementiaNeuropathological alterations in Alzheimer disease
P2860
Q22241595-09F44BD4-45D3-4268-AD1C-59651E8B1531Q22242925-7664E4AD-1D80-427D-800C-48E6392B8E26Q22252705-32B0B5C2-7ED6-4B3E-97EE-E3F559B0D4E7Q22306301-69BB46B4-94ED-40B2-A891-9F10BB270756Q24186302-D7E26D7E-DB59-49D0-87F4-339C48D84790Q24186395-87351719-0235-4847-B0F9-847C5E8A6629Q24186399-E8F39407-53CB-47ED-8535-78A2EBBD8F93Q24193707-9A54E324-240A-42B3-8A4B-359E85B1FBBEQ24194186-797B34D3-3F17-43EC-9BF0-189E609C10AEQ24194742-9EC8618A-622E-41E0-9B47-BFF1B18FA9B6Q24197654-19B84AD4-D9BC-4B6D-AA3A-0B1A22532804Q24197659-0AD53F20-FB38-4B84-8F33-A02C873D1106Q24200257-0BD55A61-B4E0-4683-BB20-7D7E52F2CF8CQ24201039-580F325D-37F4-4E11-AFF8-A7F097C503F7Q24201053-BD742CD0-600D-467B-96B0-ADD8427369C2Q24201276-F301D822-2D96-4D8D-93CA-889EDE9005F7Q24201307-5EA64E60-F8F8-4CA3-A563-56904267A8A1Q24201437-B273C5E2-6943-41B2-A9FD-0C770F9E5B70Q24201440-CBAB410C-1EE9-4F6C-847D-53CBF307FE96Q24234762-7AEDACAC-76B9-414E-A8C5-32955581DBBBQ24235058-34531164-51A9-4695-8AB4-79B99266ABF3Q24236736-D4D94404-CEF9-4741-A81A-C5CFD6BF0703Q24244668-1B87E905-7CA2-40B5-8557-A3CC8572BCF3Q24245967-2D80782A-4608-46EC-B1AE-2FE4A98DA285Q24554351-5E3A61CD-B5EF-459B-8130-7FDC633EFFC9Q24599735-E1A56A3E-C1BA-4ED7-BF58-6E3631868BF7Q24653609-924592CC-47D6-4A3D-9B88-4EBA78AC3BF5Q24657382-03678966-1FDF-4862-82D7-06B2BE333F78Q24671745-1D553EB8-76F3-43C9-948E-139D9F6D9552Q24684579-0222C213-8A83-4ADD-9916-962FF028DB09Q24685507-558B320D-AE15-4CD3-8E3C-9BC76A875185Q24802281-45585E87-8B96-4034-8274-E3B5B756635EQ24805277-C3E2945F-CA72-49F9-999B-D3EE43B1B135Q26472008-A7336415-3752-43E0-A6A7-BBF62D87C00DQ26764933-331963C7-0FBA-41BA-9341-05D3095F74A6Q26779001-E485CFB0-5F6E-43A7-AC51-5FF40ABE7D57Q26801644-732457D6-8AF8-46DC-9BC1-65F42EB4B5EFQ26849795-E664A256-5D5B-49E1-998A-E6A5B8FBFD12Q26860881-51921B69-0F5D-48C8-BF7B-729942E5B751Q27003314-217F6D6C-5F55-4C00-AE71-8B018B90AE84
P2860
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Consensus guidelines for the c ...... on DLB international workshop.
@ast
Consensus guidelines for the c ...... on DLB international workshop.
@en
Consensus guidelines for the c ...... s of dementia with Lewy bodies
@nl
type
label
Consensus guidelines for the c ...... on DLB international workshop.
@ast
Consensus guidelines for the c ...... on DLB international workshop.
@en
Consensus guidelines for the c ...... s of dementia with Lewy bodies
@nl
prefLabel
Consensus guidelines for the c ...... on DLB international workshop.
@ast
Consensus guidelines for the c ...... on DLB international workshop.
@en
Consensus guidelines for the c ...... s of dementia with Lewy bodies
@nl
P2093
P50
P921
P356
P1433
P1476
Consensus guidelines for the c ...... on DLB international workshop.
@en
P2093
Bergeron C
Collerton D
Dickson DW
Edwardson JA
P304
P356
10.1212/WNL.47.5.1113
P407
P577
1996-11-01T00:00:00Z